The widespread detection of perfluorinated acids (PFAs) in humans and known developmental toxicity in animals has raised concern about their potential effects on human reproductive health. Our objective was to determine whether increasing maternal exposure to PFAs is associated with adverse effects on fetal growth and length of gestation in women giving birth in Alberta, Canada. We examined the concentrations of perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS), and perfluorohexane sulfonate (PFHxS) in a cohort of 252 pregnant women who gave birth to live singletons. Each of the women had undergone an early second trimester prenatal screen, and her serum was analyzed for PFA concentrations. Data on infant and maternal variables were collected from the delivery record completed at birth. Adjusted changes in birth weight per natural log (ng/ml) of PFOA (median 1.5 ng/ml), PFHxS (median 0.97 ng/ml), and PFOS (median 7.8 ng/ml) were À37.4 g (95% confidence interval (CI): À86.0 to 11.2 g), 21.9 g (À23.4 to 67.2 g), and 31.3 g (À43.3 to 105.9 g), respectively. Mean birth weight z-score, standardized for gestational age and gender, length of gestation, and risk of preterm birth did not appear to be influenced by maternal PFA exposure. When PFA concentrations were divided into tertiles, similar patterns were observed. These results suggest that maternal PFA exposure has no substantial effect on fetal weight and length of gestation at the concentrations observed in this population.
Introduction
Data from animal studies have shown that the offspring of rats, mice, and rabbits exposed to perfluorinated acids (PFAs) are more susceptible to certain birth defects, including cleft palate, anasarca, and cardiac malformations Era et al., 2009) , have altered thyroid hormone homeostasis (Lau et al., 2003) , and experience delays in development (Case et al., 2001; Lau et al., 2003) . A consistent finding in many of the animal studies is a reduction in birth weight (Case et al., 2001; Thibodeaux et al., 2003; Kennedy et al., 2004) . As PFAs are widely found in human serum (Hansen et al., 2001; Houde et al., 2006) , there is concern regarding their effects on health, particularly on reproduction and fetal development.
The association between PFA exposure and fetal growth has been investigated in a series of recent epidemiological studies (Inoue et al., 2004; Apelberg et al., 2007; Fei et al., 2007; Grice et al., 2007; Monroy et al., 2008; Nolan et al., 2009; Washino et al., 2009) , with the majority of research to date having been conducted on maternal exposure to perfluorooctanoic acid (PFOA: C 7 F 15 CO 2 À ) and perfluorooctane sulfonate (PFOS: C 8 F 17 SO 3 À ). These studies have been reviewed by Olsen et al. (2009) , who concluded that there remains inconsistency in results related to fetal growth, with very little overlap in significant findings or trends. A large epidemiological study examining the effects of very high exposures to PFOA (geometric mean in serum 32.91 ng/ml) is currently ongoing (Frisbee et al., 2009) .
The uncertainty surrounding the strength and nature of any toxic effects on human fetuses at current exposure levels, in different populations, with different constellations of background risk factors, warrants further investigation. In this study we examined whether maternal exposure to PFOA, PFOS, and the structurally related, yet previously little studied perfluorohexane sulfonate (PFHxS: C 6 F 13 SO 3 À ),
as measured during the early second trimester of pregnancy, had an adverse effect on fetal growth or timing of delivery. Very little is known about the toxicological profile of PFHxS, but its half-life in human serum has been reported to be longer than PFOA or PFOS . Our sampling timeframe (2005) (2006) is somewhat more recent than previous studies, which may capture any residual risk due to declining concentrations of PFAs in humans (Olsen et al., 2008) .
Methods

Study Population
The study population was a cohort of 252 pregnant women who elected to undergo a second trimester prenatal ''triple- Only those who had been referred for the screen by a physician making at least eight similar recommendations over the course of the study period were included, in an effort to capture a more representative sample of women, rather than only those referred due to high-risk pregnancies. As these serum samples were normally discarded after the screening procedure, and linkage was anonymous, informed consent was not sought. The study protocol received ethical approval from the Health Research Ethics Board at the University of Alberta.
Exposure Assessment
The analysis of PFAs in serum was performed in-house using methods previously described in detail by Chan et al. (2009) . Briefly, PFAs were extracted by solid phase extraction (Oasis-HLB columns: 200 mg, 6 ml, Waters, Taunton, MA, USA) from 500 ml of serum spiked with 5 ng of internal standard ( 13 C-PFOS,
13
C-PFOA, Wellington Labs, Guelph, Canada). Separation was performed with an Agilent 1100 HPLC (Agilent Technologies, Palo Alto, CA, USA) by gradient elution and a Zorbax C8 column (3.5 mM, 2.1 mm Â 5 cm, Agilent Technologies). Data were collected by a hybrid triple-quadrupole linear ion trap mass spectrometer (4000 QTRAP, MDS Sciex, Concord, ON, Canada) equipped with an electrospray interface operating in negative ion mode. Multiple reaction monitoring was used to collect two to three transitions per analyte; PFHxS was quantified in the interference free 399-119 transition as described by Chan et al. (2009) .
Percent recoveries from spiked sera were used as an additional means of quality control. Briefly, serum samples were divided into 16 sets of approximately 20 samples each. Every set contained one spiked sample with 50 ng/ml of native standard and the corresponding unspiked serum sample. Freshly prepared spiked and unspiked samples were used with each spike and recovery experiment (n ¼ 16). With each analysis, 50 ng/ml of standard was spiked into a 500 ml serum sample that was taken from a larger pooled sample. This pooled sample was prepared by pooling 75 ml of randomly selected samples (n ¼ 150) from the population used in the study. Concentrations of the unspiked samples were subtracted from the spiked samples to measure the percent recovery. In the calculation of observed concentrations, the values of the blanks were subtracted from apparent concentrations in the serum samples; two blanks, just pure water, were run to monitor in-laboratory contamination with each set of 16 samples. One determination of percent recovery was carried out for each of the 16 sets. Overall bias (mean of 16 percent recovery measurements) and precision (±SD of 16 percent recovery measurements) were 99.8±15.7 for PFOA, 102±25.2 for PFHxS, and 91.1± 13.9 for PFOS. The limit of detection (LOD) was 0.25 ng/ml for each of the three compounds, which corresponds to the lowest concentration in our standard curve. The LOD was set a priori as the lowest concentration on the standard curve. Precision and accuracy of measurements, including those at LOD, are best determined from the spike-recovery experiments described in the paper. Coefficients of determination (R 2 ) for standard curves used in PFOA, PFHxS, and PFOS analyses were all greater than 0.98. Concentrations below the LOD were substituted with the value of half the LOD (0.125 ng/ml) for statistical analysis.
Outcome Assessment
The primary outcome in this study was birth weight together with other measures of fetal growth restriction, including standardized birth weight z-score and small for gestational age (SGA; birth weight o10th percentile for gestational age and infant gender (Kramer et al., 2001) ). Length of gestation (in completed weeks from last menstrual period) and preterm delivery (22-36 weeks gestation) were examined as secondary outcomes. Data were collected from delivery records that are completed at the time of birth for 499% of all hospital and midwife-attended births in the province of Alberta. This information was obtained from the Alberta Perinatal Health Program (APHP; www.aphp.com). A number of covariates were acquired from APHP, with maternal characteristics including age, weight, height, gravida, and smoking status. Maternal race and gestational age at the time of serum collection were available from data collected as a part of the prenatal screen. Infant variables from the provincial delivery record, completed at birth and stored by APHP, included gender, birth weight, and gestational age at birth.
Statistical Analysis
Linear regression was used to evaluate length of gestation, birth weight, and birth weight z-score standardized for both gender and gestational age, computed according to the equations developed for the Canadian general population by Kramer et al. (2001) . Birth weight z-scores are standardized to have a normal distribution with a mean of zero and a SD of 1.0 for each gender and gestational age greater than 22 weeks. Risk ratios (RR) and associated 95% confidence intervals (CI) were estimated for SGA and preterm delivery using Poisson regression with random subject effects and robust variance estimates (Zou, 2004) . All potential confounders were included in the regression models. Maternal age was included as a continuous variable; maternal weight (491 vs r91 kg and o45 vs Z45 kg) and height (o152 vs Z152 cm), smoking status during pregnancy (yes vs no), and infant gender were dichotomized; and maternal race and parity were included as categorical and dichotomous outcomes (Appendix). All outcomes were tested for associations with natural log-transformed and untransformed PFA concentrations, as well as concentrations divided into tertiles. The threshold for statistical significance was set at less than 5% probability of Type I error. All data analyses were conducted using Stata Version 8.0 (StataCorp, College Station, TX, USA). Power calculations were performed using PS Power and Sample Size Calculations, Version 2.1.30, February 2003 (Dupont and Plummer, 1997) .
Results
The serum samples of 252 women were analyzed for PFA concentrations. PFOA, PFHxS, and PFOS were quantified above detection limits in 91%, 93%, and 499% of samples screened, respectively. PFOA concentrations ranged from oLOD to 18 ng/ml (median 1.5 ng/ml), PFHxS ranged from oLOD to 43 ng/ml (median 0.97 ng/ml), and PFOS ranged from oLOD to 35 ng/ml (median 7.8 ng/ml) ( Table 1 ). The natural logarithms of the three compounds were correlated, with Pearson's coefficients of 0.51 for PFOA and PFHxS, 0.51 for PFOA and PFOS, and 0.52 for PFHxS and PFOS (all P-values o0.0001). The corresponding Spearman's correlation coefficients were 0.55, 0.52, and 0.54 (all P-values o0.0001).
The mean birth weight among all infants in the study population was 3349 g (SD ¼ 489 g) and the mean birth weight z-score was 0.062 (SD ¼ 0.89). Sixteen infants (6.3%) were classified as SGA at birth and 21 (8.3%) were preterm deliveries (Table 2) . With birth weight stratified by tertiles of PFA exposure, the highest concentrations were associated with higher mean birth weights. The distribution of covariates across tertiles of PFA concentrations did not reveal any pronounced trends, although the Caucasian mothers appeared to have higher PFA exposures than Asian mothers, who made up the second largest group in this population (Appendix). The associations between natural logarithms of maternal PFA concentrations and infant birth weight are given in Figure 1 . After adjustment for covariates (see footnote to Table 3 ), log units of PFAs were associated with changes in birth weight of À37.4 g (95% CI À86.0 to 11.2), 21.9 g (95% CI À23.4 to 67.2), and 31.3 g (95% CI À43.3 to 105.9) for PFOA, PFHxS, and PFOS, respectively. When PFA concentrations were included as untransformed values, the adjusted slopes for birth weight (g) per ng/ml were also not statistically significant and in the same direction: the estimates of slopes were À12.4 g (95% CI À32.8 to 8.0), 3.9 g (95% CI À8.2 to 16.0), and 1.5 g (95% CI À7.6 to 10.6) for PFOA, PFHxS, and PFOS, respectively. Mean birth weight z-score also showed no statistically significant associations with PFA concentrations after adjustment for potential confounders: estimates of slopes per log ng/ml were À0.078 (95% CI À0.19 to 0.032) for PFOA, 0.035 (95% CI À0.067 to 0.14) for PFHxS, and 0.060 (95% CI À0.11 to 0.23) for PFOS. Length of gestation was not statistically associated with PFOA or PFOS exposure, with slopes in weeks per log ng/ml of À0.06 (95% CI À0.28 to 0.15) and 0.21 (95% CI À0.12 to 0.53), respectively. Exposure to PFHxS, however, was associated with an increased length of gestation, with a slope of 0.22 (95% CI 0.03-0.42).
The effects of PFA concentration segregated into tertiles on birth outcomes, after adjustment for available covariates, are presented in Tables 3 and 4 . Neither birth weight nor its z-score reveal an exposure-response trend, but the highest tertiles of PFOS appeared to be associated with a reduced risk of SGA birth: RR 0.26 (95% CI 0.10-0.70). The risk of preterm birth appeared to decline with tertiles of exposure to PFHxS, but increase across tertiles of PFOS; only the estimates for PFHxS were statistically significant, with less risk at higher levels (RR 0.31; 95% CI 0.11-0.90). Offering continuous exposure metrics (log-transformed or not) did not alter the pattern of non-significant results seen in Table 4 (details not shown). Neither summing PFA concentrations on a molar basis, nor including all three compounds in the same model revealed any statistically significant associations (details not shown). As the model included categorical variables, alternate dichotomizations (Caucasian maternal race: yes/no and gravida ¼ 1: yes/no) were tested to ensure model stability, with no appreciable changes to the effect estimates. 
Discussion
The potential for PFAs to adversely affect fetal development has garnered much interest, and this study is the latest in a small series that has investigated the effects of these chemicals on fetal weight and length of gestation. Although there is inconsistency in the specific findings of previously conducted studies, this report is in agreement with the existing body of literature in that these results do not indicate that maternal exposure to PFOA, PFOS, or PFHxS is associated with clinically significant effects, although confounding of these results by factors related to maternal physiology cannot be ruled out (Savitz 2007) .
A summary of the literature to date, as pertaining to fetal growth, is provided in Table 5 . Of seven studies measuring the effects of PFOS, including ours, no clear trend of directionality was apparent. In this study, PFOS exposure was found to be associated with a reduced risk of SGA, but this is likely due to chance, as this does not currently have biological plausibility. Only Washino et al. (2009) found a statistically significant relationship with fetal growth (b (slope): À148.8 g per log 10 -unit; 95% CI À297.0 to À0.5). Washino et al. (2009) , however, reported that the significance of the observed effects was limited to female infants. We found no evidence for a sex-specific difference (data not shown), which is consistent with the findings of Fei et al. (2007) . There seems to be more agreement in the published data related to PFOA exposure: both Apelberg et al. (2007) and Washino et al. (2009) found non-significant reductions in birth weight associated with increasing concentrations, and Fei et al. (2007) found a statistically significant reduction of 10.63 g/ng/ml. Our results most closely mirror the latter finding, with an observed reduction of 12.4 g/ng/ml PFOA (95% CI À32.8 to 8.0). By design, our analyses were powered (80% power, 5% Type I error) to detect a change of 43 g in birth weight per ng/ml of PFOA; but had power of only 15% to detect the size of the effect reported by Fei et al. (2007) . Contrary to the above findings, Monroy et al. (2008) measured PFOA levels in a hospital-based cohort and Nolan et al. (2009) measured birth outcomes in a population highly exposed to PFOA through water contamination by local industry, and neither found evidence of an exposure-dependent restriction of fetal growth. Ours was the second study that included measure- Perfluorinated acids and fetal growth Hamm et al. ment of PFHxS. Although an increase in birth weight was observed, the CIs were very wide and this is a biologically improbable association. Monroy et al. (2008) also indicated that birth weight was not influenced by maternal PFHxS exposure, but provided no further details.
Although our results were the most similar to those of Fei et al. (2007) , it must be noted that the distribution of serum PFA concentrations in the Danish population from 1996 to 2002 was centered at higher concentrations than that of the current study (Table 5 ). However, Apelberg et al. in 2004 , Monroy et al. in 2004 -2005 , and Washino et al. in 2002 reported comparable ranges of PFA concentrations to the current study (Table 5 ). Although this study and those of Monroy et al. (2008) and Washino et al. (2009) were conducted using maternal samples (collected at delivery and at 23-35 weeks of gestation, respectively), the analyses of Apelberg et al. (2007) were based on cord blood samples, which are known to have a lower concentration of PFAs than samples taken from pregnant mothers (Inoue et al., 2004; Midasch et al., 2007; Monroy et al., 2008) . The varying concentrations across studies may reflect the phasing-out of perfluorooctyl chemicals in the past decade. Olsen et al. (2008) found evidence that plasma/serum concentrations of PFOS, PFOA, and PFHxS decreased between 2000 and 2006, which may explain why the concentrations observed by Fei et al. (2007) between 1996 and 2002 were much higher than those of our study and those of Monroy et al. (2008) ; Washino et al. (2009); Apelberg et al. (2007) , which were all conducted between 2002 and 2006. In addition, it is likely that systematic differences in exposure exist geographically.
Although the effects of PFOS and PFOA have both been appraised in previous works, our study also included measurements of PFHxS, which has only been included in the report of Monroy et al. (2008) . Previous studies may have excluded PFHxS due to interferences in serum samples, but we used a highly specific technique that avoided these here (Chan et al., 2009) . As a result, our methods may have allowed for better sensitivity in detecting PFHxS at lower concentrations. Note that our LOD (0.25 ng/ml) was approximately four times lower than that reported by Monroy et al. (2008) (1.12 ng/ml), which allowed for the inclusion of a greater number of PFHxS data points above LOD in this study: 93% in our work, compared with 45.5% in Monroy et al. (2008) . Chan et al. (2009) also demonstrated that the method used by Monroy et al. (2008) , unlike the one we adopted, reports positively biased concentrations of PFHxS. Overall, our results seem to be the most informative among those published to date about the impact of actual exposure to PFHxS on birth outcomes in humans.
Our study population was selected from women who were undergoing a screening procedure typically recommended for older expectant mothers. Thus, although we made an effort to limit this source of bias by restricting the cohort to women recommended for the screen by physicians who seemed to recommend a substantial proportion of their patients for the blood test, it is likely that our cohort is still biased toward the inclusion of older women who have access to quality prenatal care (mean age: 31.2 years; provincial average: 29.0 years (Tough et al., 2006) ). However, there is no reason to suspect that these women would be at a higher risk for increased PFA exposure and indeed, a trend in maternal age was not found (Appendix). However, caution is required in interpreting this finding, as a recent biomonitoring program in the province of Alberta found statistically lower PFOA concentrations in older pregnant women (Gabos et al., 2008) . Maternal PFA exposure was determined only from one point in pregnancy, at 15-16 weeks of gestation. Although Monroy et al. (2008) showed that PFA levels in maternal serum decline throughout pregnancy (from 24-28 weeks to time of delivery); data collected by Fei et al. (2007) during the first and second trimesters suggested that PFA concentrations remain stable over this period, which is most relevant to our research question.
Taken together, these results do not suggest that maternal PFA exposure has a substantial effect on fetal weight and length of gestation. This is consistent with the overall picture that emerges from the literature to date, which shows that PFA exposure is not associated with clinically relevant birth outcomes. However, the integrated assessment of the literature may be seen as supporting a small effect of PFOA on birth weight, but is equally consistent with the random fluctuations of the estimates from different studies around the null.
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